HC Wainwright reaffirmed their buy rating on shares of X4 Pharmaceuticals (NASDAQ:XFOR – Free Report) in a research note published on Tuesday,Benzinga reports. HC Wainwright currently has a $1.50 price objective on the stock.
Separately, Stifel Nicolaus reduced their target price on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th.
Check Out Our Latest Stock Report on XFOR
X4 Pharmaceuticals Trading Up 0.0 %
Institutional Trading of X4 Pharmaceuticals
A number of large investors have recently modified their holdings of the company. Verition Fund Management LLC purchased a new position in X4 Pharmaceuticals during the 3rd quarter worth $30,000. SG Americas Securities LLC purchased a new position in shares of X4 Pharmaceuticals during the third quarter valued at $37,000. XTX Topco Ltd bought a new stake in shares of X4 Pharmaceuticals in the second quarter valued at about $65,000. Rhumbline Advisers lifted its stake in X4 Pharmaceuticals by 14.6% in the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock worth $109,000 after acquiring an additional 23,831 shares during the period. Finally, Jane Street Group LLC grew its holdings in X4 Pharmaceuticals by 103.4% during the 3rd quarter. Jane Street Group LLC now owns 248,447 shares of the company’s stock worth $166,000 after acquiring an additional 126,296 shares in the last quarter. Hedge funds and other institutional investors own 72.03% of the company’s stock.
X4 Pharmaceuticals Company Profile
X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.
Read More
- Five stocks we like better than X4 Pharmaceuticals
- Health Care Stocks Explained: Why You Might Want to Invest
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- What Are Treasury Bonds?
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- Do ETFs Pay Dividends? What You Need to Know
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.